Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage...

Full description

Bibliographic Details
Main Authors: Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Endocrinology
Subjects:
bone mineral density
teriparatide
denosumab
bisphosphonate
glucocorticoid-induced osteoporosis
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/full

Similar Items